Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial

Charles M Morin, Jack D Edinger, Andrew D Krystal, Daniel J Buysse, Simon Beaulieu-Bonneau, Hans Ivers, Charles M Morin, Jack D Edinger, Andrew D Krystal, Daniel J Buysse, Simon Beaulieu-Bonneau, Hans Ivers

Abstract

Background: Chronic insomnia is a prevalent disorder associated with significant psychosocial, health, and economic impacts. Cognitive behavioral therapies (CBTs) and benzodiazepine receptor agonist (BzRA) medications are the most widely supported therapeutic approaches for insomnia management. However, few investigations have directly compared their relative and combined benefits, and even fewer have tested the benefits of sequential treatment for those who do not respond to initial insomnia therapy. Moreover, insomnia treatment studies have been limited by small, highly screened study samples, fixed-dose, and fixed-agent pharmacotherapy strategies that do not represent usual clinical practices. This study will address these limitations.

Methods/design: This is a two-site randomized controlled trial, which will enroll 224 adults who meet the criteria for a chronic insomnia disorder with or without comorbid psychiatric disorders. Prospective participants will complete clinical assessments and polysomnography and then will be randomly assigned to first-stage therapy involving either behavioral therapy (BT) or zolpidem. Treatment outcomes will be assessed after 6 weeks, and treatment remitters will be followed for the next 12 months on maintenance therapy. Those not achieving remission will be offered randomization to a second, 6-week treatment, again involving either pharmacotherapy (zolpidem or trazodone) or psychological therapy (BT or cognitive therapy (CT)). All participants will be re-evaluated 12 weeks after the protocol initiation and at 3-, 6-, 9-, and 12-month follow-ups. Insomnia remission, defined categorically as a score < 8 on the Insomnia Severity Index, a patient-reported outcome, will serve as the primary endpoint for treatment comparisons. Secondary outcomes will include sleep parameters derived from daily sleep diaries and from polysomnography, subjective measures of fatigue, mood, quality of life, and functional impairments; and measures of adverse events; dropout rates; and treatment acceptability. Centrally trained therapists will administer therapies according to manualized, albeit flexible, treatment algorithms.

Discussion: This clinical trial will provide new information about optimal treatment sequencing and will have direct implication for the development of clinical guidelines for managing chronic insomnia with and without comorbid psychiatric conditions.

Trial registration: ClinicalTrials.gov Identifier: NCT01651442 , Protocol version 4, 20 April 2011, registered 26 June 2012.

Figures

Fig. 1
Fig. 1
Flow chart of study design

References

    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) 5. Washington, DC: American Psychiatric Publishing; 2013.
    1. Edinger JD, Bonnet MH, Bootzin RR, Doghramji K, Dorsey CM, Espie CA, et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep. 2004;27:1567–96.
    1. American Academy of Sleep Medicine . International Classification of Sleep Disorders: Diagnostic and Coding Manuel. 2. Westchester: American Academy of Sleep Medicine; 2005.
    1. American Academy of Sleep Medicine . International Classification of Sleep Disorders: Diagnostic and Coding Manuel, 3rd ed (ICSD-3) 3. Westchester: American Academy of Sleep Medicine; 2014.
    1. Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC. Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biol Psychiatry. 2006;60:1364–71. doi: 10.1016/j.biopsych.2006.05.039.
    1. Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111. doi: 10.1053/smrv.2002.0186.
    1. Morin CM, LeBlanc M, Daley M, Grégoire JP, Mérette C. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7:123–30. doi: 10.1016/j.sleep.2005.08.008.
    1. Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10–9. doi: 10.1016/j.jad.2011.01.011.
    1. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262:1479–84. doi: 10.1001/jama.1989.03430110069030.
    1. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol. 1997;146:105–14. doi: 10.1093/oxfordjournals.aje.a009241.
    1. Buysse DJ, Tu XM, Cherry CR, Begley AE, Kowalski J, Kupfer DJ, et al. Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biol Psychiatry. 1999;45:205–13. doi: 10.1016/S0006-3223(98)00198-X.
    1. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, 3rd, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60:221–5. doi: 10.4088/JCP.v60n0403.
    1. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord. 1997;42:209–12. doi: 10.1016/S0165-0327(96)01411-5.
    1. Leger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14:379–89. doi: 10.1016/j.smrv.2010.01.003.
    1. Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J. The economic burden of insomnia: Direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009;32:55–64.
    1. Krystal A. Sleep Disorders: Neuropharmacology. In: Sleep Research Society, editor. Basics of Sleep Guide. 2nd ed. Darien, Illinois, Sleep Research Society, 2009.
    1. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep. 1999;22:371–5.
    1. Morin CM, Espie CA. Insomnia: a clinical guide to assessment and treatment. New York: Kluwer Academic/Plenum; 2003.
    1. Edinger JD, Means MK. Cognitive-behavioral therapy for primary insomnia. Clin Psychol Rev. 2005;25:539–58. doi: 10.1016/j.cpr.2005.04.003.
    1. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J. 2000;162:225–33.
    1. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA. 1997;278:2170–7. doi: 10.1001/jama.1997.03550240060035.
    1. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11. doi: 10.1176/appi.ajp.159.1.5.
    1. Perlis ML, Smith MT, Orff H, Enright T, Nowakowski S, Jungquist C, et al. The effects of Modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. Sleep. 2004;27:715–25.
    1. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008; 31:79–90.
    1. Roehrs TA, Randall S, Harris E, Maan R, Roth T. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 2012;26:1088–95. doi: 10.1177/0269881111424455.
    1. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052–60. doi: 10.1016/j.biopsych.2006.01.016.
    1. Smith WT, Londborg PD, Glaudin V, Painter JR, Summit RN. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord. 2002;70:251–9. doi: 10.1016/S0165-0327(01)00352-4.
    1. Buysse DJ, Reynolds CF, 3rd, Houck PR, Perel JM, Frank E, Begley AE, et al. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? J Clin Psychiatry. 1997;58:426–32. doi: 10.4088/JCP.v58n1003.
    1. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep. 2004;27:1441–2.
    1. Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002;14:143–7. doi: 10.3109/10401230209147450.
    1. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069–72. doi: 10.1176/ajp.151.7.1069.
    1. Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53:83–5.
    1. Roy AN, Smith M. Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization. Sleep Med. 2010;11:462–9. doi: 10.1016/j.sleep.2009.09.012.
    1. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: A meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172–80. doi: 10.1176/ajp.151.8.1172.
    1. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004) Sleep. 2006;29:1398–414.
    1. Vitiello MV, McCurry SM, Shortreed SM, Balderson BH, Baker LD, Keefe FJ, et al. Cognitive-behavioral treatment for comorbid insomnia and osteoarthritis pain in primary care: The lifestyles randomized controlled trial. J Am Geriatr Soc. 2013;61:947–56. doi: 10.1111/jgs.12275.
    1. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol. 2005;23:6083–96. doi: 10.1200/JCO.2005.09.548.
    1. Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients: A randomized clinical trial. Arch Intern Med. 2005;165:2527–35. doi: 10.1001/archinte.165.21.2527.
    1. Rybarczyk B, Lopez M, Benson R, Alsten C, Stepanski E. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging. 2002;17:288–98. doi: 10.1037/0882-7974.17.2.288.
    1. Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008;31:489–95.
    1. Taylor DJ, Lichstein KL, Weinstock J, Sanford S, Temple JR. A pilot study of cognitive-behavioral therapy of insomnia in people with mild depression. Behav Ther. 2007;38:49–57. doi: 10.1016/j.beth.2006.04.002.
    1. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504.
    1. Morin CM. Combined therapeutics for insomnia: Should our first approach be behavioral or pharmacological? Sleep Med. 2006;7(Suppl 1):S15–9. doi: 10.1016/j.sleep.2006.03.005.
    1. Edinger JD, Sampson WS. A primary care “friendly” cognitive behavioral insomnia therapy. Sleep. 2003;26:177–82.
    1. Mimeault V, Morin CM. Self-help treatment for insomnia: Bibliotherapy with and without professional guidance. J Consult Clin Psychol. 1999;67:511–9. doi: 10.1037/0022-006X.67.4.511.
    1. Ritterband LM, Thorndike FP, Gonder-Frederick LA, Magee JC, Bailey ET, Saylor DK, et al. Efficacy of an internet-based behavioral intervention for adults with insomnia. Arch Gen Psychiatry. 2009;66:692–8. doi: 10.1001/archgenpsychiatry.2009.66.
    1. Espie CA. “Stepped care”: A health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep. 2009;32:1549–58.
    1. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial. JAMA. 1999;281:991–9. doi: 10.1001/jama.281.11.991.
    1. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Arch Intern Med. 2004;164:1888–96. doi: 10.1001/archinte.164.17.1888.
    1. Wu R, Bao J, Zhang C, Deng J, Long C. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychother Psychosom. 2006;75:220–8. doi: 10.1159/000092892.
    1. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295:2851–8. doi: 10.1001/jama.295.24.2851.
    1. Morin CM, Vallières A, Guay B, Ivers H, Savard J, Mérette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301:2005–15. doi: 10.1001/jama.2009.682.
    1. Schaefer K, McCall W, Krystal A, Rubens R, Wilson P, Pfleeger K, et al. Relative effect sizes of eszopiclone treatment for insomnia in patients with primary insomnia and insomnia co-morbid with major depressive disorder, generalized anxiety disorder, perimenopausal transition and rheumatoid arthritis. Annual Meeting of the Associate Professional Sleep Societies; Minneapolis, Minnesota. 2007.
    1. Morin CM. Insomnia: Psychological assessment and management. New York: Guilford Press; 1993.
    1. Edinger JD, Kirby A, Lineberger M, Loiselle M, Wohlgemuth W, Means M. Duke structured interview for sleep disorders. Durham: University Medical Center; 2004.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) Washington, DC: American Psychiatric Association; 2000.
    1. Edinger JD, Wyatt JK, Olsen MK, Stechuchak KM, Carney CE, Chiang A. Reliability and validity of the Duke Structured Interview for Sleep Disorders for insomnia screening. 23rd Annual Meeting of the Associated Professionnal Sleep Societies. Seatle: LLC; 2009.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version. Washington, D.C.: American Psychiatric Publishing; 1997.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. doi: 10.1016/0022-3956(75)90026-6.
    1. American Academy of Sleep Medicine . The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Chicago: Author; 2007.
    1. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. doi: 10.1016/S1389-9457(00)00065-4.
    1. Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34:601–8.
    1. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315–25. doi: 10.1016/0022-3999(94)00125-O.
    1. Ware JE, Jr, The SCD. MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83. doi: 10.1097/00005650-199206000-00002.
    1. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–4. doi: 10.1192/bjp.180.5.461.
    1. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: TX: The Psychological Corporation; 1996.
    1. Spielberger CD. Manual for the State-Trait Anxiety Inventory (STAI) Palo Alto: Consulting Psychologists Press; 1983.
    1. Guy W, Wilson WH, Brooking B, Manov G, Fjetland O. Reliability and validity of SAFTEE: preliminar analyses. Psychopharmacol Bull. 1986;22:397–401.
    1. Devilliya GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73–86. doi: 10.1016/S0005-7916(00)00012-4.
    1. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep. 1987;10:45–56.
    1. Bootzin RR, Epstein D, Wood JM. Stimulus Control Instructions. In: Hauri P, editor. Case Studies in Insomnia. New York: Plenum Press; 1991. pp. 19–28.
    1. Harvey AG, Sharpley AL, Ree MJ, Stinson K, Clark DM. An open trial of cognitive therapy for chronic insomnia. Behav Res Ther. 2007;45:2491–501. doi: 10.1016/j.brat.2007.04.007.
    1. Harvey AG. Insomnia, psychiatric disorders, and the transdiagnostic perspective. Curr Dir Psychol Sci. 2008;17:299–303. doi: 10.1111/j.1467-8721.2008.00594.x.
    1. Cascade EF, Kalali AH, Reites J. Current status of hypnotic prescribing habits in the United States. Psychiatry. 2007;4:24–5.
    1. Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60:668–76. doi: 10.4088/JCP.v60n1005.
    1. Walsh JK, Erman M, Erwin C. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191–8. doi: 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>;2-X.
    1. Little RJA, Rubin DB, editors. Statistical Analysis with Missing Data (2nd edition) New York: Wiley; 2002.
    1. Rotnitzky A, Scharfstein D, Su TL, Robins J. Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring. Biometrics. 2001;57:103–13. doi: 10.1111/j.0006-341X.2001.00103.x.
    1. Brown H, Prescott R. Applied Mixed Models in Medicine. 2. New York: Wiley; 2006.
    1. Stroup WW. Mixed model procedures to assess power, precision and sample size in the design of experiments. American Statistical Association: Baltimore; 1999.
    1. Dahmen G, Rochon J, Konig IR, Ziegler A. Sample size calculations for controlled clinical trials using generalized estimating equations (GEE) Methods Inf Med. 2004;43:451–6.
    1. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: A randomized controlled trial. JAMA. 2001;285:1856–64. doi: 10.1001/jama.285.14.1856.
    1. Ong JC, Kuo TF, Manber R. Who is at risk for dropout from group cognitive-behavior therapy for insomnia? J Psychosom Res. 2008;64:419–25. doi: 10.1016/j.jpsychores.2007.10.009.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj